Efficacy of forskolin as a promising therapy for chronic olfactory dysfunction post COVID-19

Mohamed H. Abdelazim,Faisal Alsenani,Mohammed Alnuhait,Abdullah S. Alshammari,Abdullah H. Altemani,Eyad A. Althagafi,Dania S. Waggas,Ahmed H. Abdelazim,Adnan Alharbi
DOI: https://doi.org/10.1007/s00405-024-08802-x
2024-07-14
European Archives of Oto-Rhino-Laryngology
Abstract:Olfactory dysfunction is increasingly common among COVID-19 patients, impacting their well-being. Reports have demonstrated decreased levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate among patients with chronic olfactory dysfunction. A prospective randomized clinical trial was developed to demonstrate the efficacy of an oral forskolin regimen treatment, an adenylyl cyclase activator that raises intracellular levels of cyclic adenosine monophosphate, for the treatment of olfactory dysfunction following COVID-19, compared to placebo regimen.
otorhinolaryngology
What problem does this paper attempt to address?